<DOC>
	<DOCNO>NCT01308021</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety grass pollen-derived peptide administrate orally treat seasonal allergic rhinoconjunctivitis .</brief_summary>
	<brief_title>Clinical Efficacy Safety gpASIT+TM Treat Seasonal Allergic Rhinoconjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<criteria>Age 18 50 year Subject give write informed consent The subject good physical mental health accord his/her medical history , vital sign , clinical status Male non pregnant , nonlactating female Female unable bear child must documentation CRF ( i.e . tubule ligation , hysterectomy , post menopausal ( define minimum one year since last menstrual period ) ) Allergy &gt; 2 year Subjects current immunotherapy subject underwent previous immunotherapy within last 2 year Subjects perennial asthma Subjects VC &lt; 80 % FEV1 &lt; 70 % Subjects require controller medication asthma ( bronchodilator nebulised drug local systemic corticosteroid ) Documented evidence chronic sinusitis ( determined investigator ) Subjects history hepatic renal disease Subjects symptomatic perennial inhalant allergen Subject malignant disease , autoimmune disease Female subject pregnant , lactating , childbearing potential protected pregnancy sufficiently reliable method ( OCs , IUD , ... ) Any chronic disease , may impair subject 's ability participate trial ( i.e . severe congestive heart failure , active gastric ulcer , inflammatory bowel disease , uncontrolled diabetes mellitus , etc… ) Subjects require betablockers medication Chronic use concomitant medication would affect assessment effectiveness trial medication ( e.g . tricyclic antidepressant ) Subject febrile illness ( &gt; 37.5°C , oral ) A know positive serology HIV1/2 , HBV HCV The subject immunocompromised medication illness , receive vaccine , corticoid immunosuppressive medication within 1 month trial entry Receipt blood blood derivative past 6 month precede trial entry Regular consumption corticoid ( oral , topic nasal ) antihistaminic drug within 4 week precede trial Any consumption corticoid ( oral , topic nasal ) antihistaminic drug within 1 week precede trial Use longacting antihistamine Any condition could incompatible protocol understand compliance Subjects forfeit freedom administrative legal award guardianship Unreliable subject include noncompliant subject , subject know alcoholism drug abuse history serious psychiatric disorder well subject unwilling give inform consent abide requirement protocol Participation another clinical trial and/or treatment experimental drug within last 2 year A history hypersensitivity excipients Rhinitis medicamentosa , nonspecific rhinitis ( food dye , preservative agent… ) Subjects without mean contact investigator rapidly case emergency , able contact rapidly investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Rhinoconjunctivitis</keyword>
	<keyword>Allergy</keyword>
	<keyword>Grass pollen</keyword>
	<keyword>Hypersensitivity</keyword>
	<keyword>Immune system disorder</keyword>
</DOC>